(Q43752162)

26 November 2017

title

Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac (English)

1 reference

26 November 2017

Yordanov AT

1

1 reference

26 November 2017

Garmestani K

2

1 reference

26 November 2017

Zhang M

3

1 reference

26 November 2017

Zhang Z

4

1 reference

26 November 2017

Yao Z

5

1 reference

26 November 2017

Phillips KE

6

1 reference

26 November 2017

Herring B

7

1 reference

26 November 2017

Horak E

8

1 reference

26 November 2017

Beitzel MP

9

1 reference

26 November 2017

Schwarz UP

10

1 reference

26 November 2017

Gansow OA

11

1 reference

26 November 2017

Plascjak PS

12

1 reference

26 November 2017

Eckelman WC

13

1 reference

26 November 2017

Waldmann TA

14

1 reference

26 November 2017

Brechbiel MW

15

1 reference

26 November 2017

publication date

1 October 2001

1 reference

Nuclear Medicine and Biology

26 November 2017

published in

1 reference

26 November 2017

volume

28

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

845-856

1 reference

The preparation of astatine labelled proteins

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Tumour localisation of 211At-labelled monoclonal antibody to a sub-cutaneous human heterograft in the nude mouse II

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Preparation of a 211At-IgG conjugate which is stable in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Radioimmunotherapy with alpha-emitting nuclides

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

A humanized antibody that binds to the interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

The specific inhibition of cellular clonogenic proliferation using 211At labelled lectins and antibodies--I

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

The in vivo fate of a 21 211AT labelled monoclonal antibody witknown specificity in a murine system

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

The preparation of astatine labelled proteins using an electrophilic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

The biological behaviour of some organic astatine compounds in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Radioimmunotherapy: recent results and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2801%2900257-8

7 January 2021

10.1016/S0969-8051(01)00257-8

Identifiers

DOI

1 reference

26 November 2017

1 reference